Q-Line Biotech Ltd.
•Add ratio to table
ABOUT
KEY POINTS
Revenue Breakup Mar 2026 • Manufacturing: 67.5% • Trading: 32.5%
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
CONS
- Receivables are growing faster than sales - a possible quality concern
- Working capital days have increased from 99 to 138 days
- Total debt has risen sharply - up 33.4% year on year
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| LENSKART | 694.05 | 184.20 | 120716.54 | 0.00 | 2284.30 | 3634.35 | 27141.80 | 1332.69 | 12.55 | 21.70 |
| POLYMED | 1723.80 | 55.45 | 17472.69 | 0.20 | 85.27 | -8.39 | 525.38 | 30.30 | 14.05 | 24.11 |
| MOLBIO | 1258.10 | 87.03 | 14498.34 | 0.00 | 527.44 | — | 4083.76 | — | 19.79 | 24.63 |
| QLINE | 675.70 | 28.29 | 1576.29 | 0.00 | — | — | — | — | 23.00 | — |
| 3BBLACKBIO | 1472.10 | 22.75 | 1263.45 | 0.34 | 8.98 | -28.99 | 33.49 | 50.59 | 26.03 | 25.45 |
| LAXMIDENTL | 200.40 | 35.70 | 1102.79 | 0.00 | 10.32 | 23.83 | 74.70 | 16.13 | 24.96 | 20.26 |
| GKB | 66.13 | 10.28 | 33.33 | 0.00 | 1.85 | 387.99 | 33.04 | 2.26 | 8.82 | 7.97 |
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
No standalone quarterly results found
We don't have this information yet. Please check back later.
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2025 | Mar 2026 | |
|---|---|---|
| 313 | 341 | |
| 251 | 242 | |
| Operating Profit | 62 | 99 |
| OPM % | 19.91% | 29.07% |
| 26 | 5 | |
| Interest | 15 | 19 |
| Depreciation | 7 | 11 |
| Profit before Tax | 67 | 74 |
| Tax % | 28.77% | 23.27% |
| Net Profit | 47 | 57 |
| EPS | 300.93 | 34.99 |
| Dividend Payout % | 0.00% | 0.00% |
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
- 1 Year:
- —
RETURN ON EQUITY
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
- Last Year:
- 26%
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 2 | 16 |
| 188 | 231 | |
| 134 | 178 | |
| Trade Payables | 56 | 52 |
| 68 | 69 | |
| Total Liabilities | 448 | 547 |
| 73 | 141 | |
| Capital Work in Progress | 59 | 15 |
| 18 | 17 | |
| 90 | 95 | |
| 83 | 127 | |
| Cash & Bank | 44 | 76 |
| 80 | 76 | |
| Total Assets | 448 | 547 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2025 | Mar 2026 | |
|---|---|---|
| 22 | 21 | |
| Cash from Investing | -75 | -29 |
| Cash from Financing | 46 | 36 |
| -7 | 28 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2025 | Mar 2026 | |
|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
No announcements filed.
News
Recent coverage and analyst commentary for QLINE
Loading news…
AI Stock Analyst
Q-Line Biotech Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account